There are currently 12 active clinical trials seeking participants for Systemic Sclerosis research studies. The states with the highest number of trials for Systemic Sclerosis participants are California, New York, Pennsylvania and Texas.
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases
NCT05869955
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Local Institution - 0035, Aurora, Colorado +49 locations
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Register for Updates
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
NCT05029336
Recruiting
A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy. This study proposes... Read More
Gender:
All
Ages:
Between 8 years and 25 years
Trial Updated:
06/11/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Register for Updates
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777
Recruiting
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/06/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
NCT05462522
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of RO7303509 treatment in participants with systemic sclerosis (SSc) during a multiple-ascending-dose (MAD) portion of the trial. In the MAD phase, increasing doses of study drug will be tested sequentially. For each dose tested, the MAD stage will consist of a treatment period of 12 weeks followed by either a safety follow-up period of 13 weeks or continued treatment in an optional open-label safety ext... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/30/2024
Locations: Stanford University, Palo Alto, California +42 locations
Conditions: Systemic Sclerosis
Register for Updates
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803
Recruiting
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/24/2024
Locations: Research Site, Birmingham, Alabama +184 locations
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
NCT05989763
Recruiting
The purpose of this study is to determine whether transcutaneous electrical acustimulation (TEA) alters systemic sclerosis (SSc)-related colonic and anorectal physiology by enhancing autonomic nervous system (ANS) function. The study will examine the effects of TEA on slow colonic transit (SCT) and rectal hyposensitivity (RH), to examine whether TEA improves autonomic dysfunction and modulates inflammatory pathways.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Systemic Sclerosis, Constipation, Gastrointestinal Motility Disorder, Autonomic Dysfunction
Register for Updates
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
NCT05715463
Recruiting
Social determinants of health (SDoH), defined by the World Health Organization as "the conditions in which people are born, grow, work, live and age and the wider set of forces and systems shaping the conditions of daily life" are estimated to be responsible for nearly 90 percent of a person's health outcomes. SDoH are key contributors to racial, ethnic and socioeconomic disparities in care healthcare access and health outcomes. The goal of this clinical trial is to identify patients with inflam... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/07/2024
Locations: Brigham & Women's Hospital, Boston, Massachusetts
Conditions: Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Register for Updates
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
NCT03844061
Recruiting
This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab & Rituximab or placebo.Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously. Placebo injections and infusions will be of normal saline. Randomization will be don... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/28/2024
Locations: Hospital for Special Surgery, New York, New York
Conditions: Systemic Sclerosis
Register for Updates
Rheumatology Patient Registry and Biorepository
NCT04402086
Recruiting
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
12/21/2023
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Register for Updates
RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis
NCT05298358
Recruiting
This is a Phase I, single arm, open label, single center pilot study to assess a reduced-intensity conditioning regimen, bone marrow transplantation with high dose cyclophosphamide (PTCy) in recipients with refractory systemic sclerosis. This study expects to enroll 15 donor/recipient pairs for a total of 30 participants. The primary objective of this study is to assess the safety of using a reduced intensity condition (RIC) preparative regimen bone marrow transplant (BMT) with post-transplant... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/11/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Systemic Sclerosis
Register for Updates
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT03630211
Recruiting
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Gender:
All
Ages:
Between 8 years and 60 years
Trial Updated:
09/07/2023
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania +2 locations
Conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
New Orleans Pulmonary Hypertension Biobank
NCT03269630
Recruiting
Pulmonary hypertension (PH) is a serious condition characterized by a mean pulmonary artery pressure >=25mmHg on right heart catheterization (RHC). Despite advances in PH care, outcomes are still sub-optimal and further research is required into the pathobiology of the disease and development of biomarkers that can guide clinical care. The investigators are establishing a biobank to collect samples (blood, urine, stool) from patients with pulmonary hypertension, patients at high risk for pulmona... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: University Medical Center-New Orleans, New Orleans, Louisiana
Conditions: Pulmonary Hypertension, Systemic Sclerosis, Mixed Connective Tissue Disease, Heart Failure With Normal Ejection Fraction, Healthy
Register for Updates